The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 05, 2021

Filed:

Oct. 26, 2016
Applicants:

Immunolight, Llc, Detroit, MI (US);

Duke University, Durham, NC (US);

Inventors:

Mark Oldham, Durham, NC (US);

Justus Adamson, Durham, NC (US);

Mark W. Dewhirst, Durham, NC (US);

Paul Yoon, Durham, NC (US);

Harold Walder, Belville, NC (US);

Frederic A. Bourke, Jr., Greenwich, CT (US);

Zakaryae Fathi, Raleigh, NC (US);

Wayne F. Beyer, Jr., Bahama, NC (US);

Assignees:

IMMUNOLIGHT, LLC, Detroit, MI (US);

DUKE UNIVERSITY, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 41/00 (2020.01); A61K 31/409 (2006.01); A61N 5/06 (2006.01); A61K 31/655 (2006.01); A61K 33/02 (2006.01); A61K 31/525 (2006.01); A61K 31/352 (2006.01); A61K 31/403 (2006.01); A61K 33/24 (2019.01); A61N 5/10 (2006.01); A61K 31/426 (2006.01); A61K 31/47 (2006.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 41/0066 (2013.01); A61K 31/352 (2013.01); A61K 31/403 (2013.01); A61K 31/409 (2013.01); A61K 31/525 (2013.01); A61K 31/655 (2013.01); A61K 33/02 (2013.01); A61K 33/24 (2013.01); A61N 5/062 (2013.01); A61N 5/0624 (2013.01); A61N 5/10 (2013.01); A61K 31/426 (2013.01); A61K 31/47 (2013.01); A61K 2300/00 (2013.01); A61N 2005/065 (2013.01); A61N 2005/1095 (2013.01); A61N 2005/1098 (2013.01); B82Y 5/00 (2013.01); Y02A 50/30 (2018.01);
Abstract

A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.


Find Patent Forward Citations

Loading…